Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. [electronic resource]
Producer: 20150109Description: 1750-6 p. digitalISSN:- 1532-1827
- Adult
- Afatinib
- Aged
- Aged, 80 and over
- Animals
- Apoptosis -- drug effects
- Cell Cycle -- drug effects
- Cell Proliferation -- drug effects
- Cystadenocarcinoma, Serous -- drug therapy
- Endometrial Neoplasms -- drug therapy
- Female
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization, Fluorescence
- In Vitro Techniques
- Mice
- Mice, SCID
- Middle Aged
- Phosphorylation -- drug effects
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- genetics
- Signal Transduction -- drug effects
- Tumor Cells, Cultured
- Uterine Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.